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OBJECTIVES This prospective study was undertaken to correlate early and late metaiodobenzylguanidine
(MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with
heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2).
BACKGROUND The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure.
Whether it is related to exercise capacity and has better prognostic value than peak VO2 is
unknown.
METHODS Ninety-three patients with heart failure (ejection fraction ,45%) were studied with planar
MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n 5 44). Early (20 min)
and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined.
Prognostic value was assessed by survival curves (Kaplan–Meier method) and uni- and
multivariate Cox analyses.
RESULTS Late cardiac MIBG uptake was reduced (131 6 20%, normal values 192 6 42%) and
correlated with ejection fraction (r 5 0.49), cardiac index (r 5 0.40) and pulmonary wedge
pressure (r 5 20.35). There was a significant correlation between peak VO2 and MIBG
uptake (r 5 0.41, p , 0.0001). With a mean follow-up of 10 6 8 months, both late MIBG
uptake (p 5 0.04) and peak VO2 (p , 0.0001) were predictive of death or heart
transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG
uptake nor WO yielded significant insights beyond those provided by late MIBG uptake.
CONCLUSIONS Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart
failure, but peak VO2 remains the most powerful prognostic index. (J Am Coll Cardiol 1999;
33:759–66) © 1999 by the American College of Cardiology
Patients with chronic heart failure (CHF) have reduced
exercise capacity (1) attributable to both central and periph-
eral factors (2). Alteration of the cardiac adrenergic pathway
is a hallmark of the syndrome (3,4), participating in the
reduction in the heart rate and contractile reserves. To what
extent it may contribute to the reduction of exercise capacity
has not been previously determined. Metaiodobenzylguani-
dine (MIBG), an analogue of noradrenaline that shares the
same reuptake pathway within the cardiac synapse (5), was
developed to visualize sympathetic innervation and was
recently used to study myocardial adrenergic nerve activity
(6,7). Its myocardial fixation depends on the integrity of the
sympathetic pathway, is reduced in parallel with the alter-
ation of norepinephrine uptake (8,9) and correlates in
experimental heart failure with the myocardial content of
norepinephrine (10) and in patients with the degree of
myocyte degeneration and necrosis (11). Whether MIBG
uptake should be assessed early or late after injection
remains debated (12–17); the washout rate of MIBG uptake
from early to late imaging may reflect the sympathetic
nervous system activity. It is unclear at the present time,
however, whether imaging MIBG uptake early and late
after injection has some clinical value above only late
imaging. The relationships between MIBG uptake and
hemodynamics have not been extensively studied (5,18).
Finally, it has recently been shown that MIBG uptake had
a high prognostic value (19) and may help successfully
manage the transplant list (20), but the comparison with
another major prognostic index, peak exercise oxygen up-
take (peak VO2) (21,22), has not yet been performed. As
the latter has clearly appeared as the best index of prognosis
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in most of the recent studies, we wondered which index had
the greatest value to predict outcome in patients with
various degrees of heart failure.
The aims of the present study were therefore 1) to address
the relationships between MIBG cardiac uptake and cardiac
hemodynamics and exercise capacity; 2) to prospectively
compare the prognostic values of cardiac MIBG uptake and
peak VO2, and 3) to compare early and late MIBG
acquisitions, in patients with CHF.
METHODS
Patients. Ninety-three consecutive patients with CHF (88
men, 5 women) were prospectively studied during an
18-month period. Their mean age was 55 6 10 years (range
32 to 77). The inclusion criteria were a history of chronic
heart failure and a left ventricular ejection fraction (EF)
lower than 45%. The etiology of heart failure was an
ischemic cardiomyopathy in 24 cases and a dilated cardio-
myopathy in 69 cases. Forty patients were in New York
Heart Association (NYHA) functional class II, 46 in class
III and 7 in class IV. All were in stable conditions. At the
time of the study, most of the patients were receiving
angiotensin-converting enzyme inhibitors (86%) and di-
uretics (92%); 45% received digoxin, 42% nitrates, 40%
amiodarone and 13% a beta-adrenergic blocking agent.
Eighty-seven patients had echocardiography for measure-
ment of left ventricular end-diastolic and end-systolic di-
ameters and calculation of fractional shortening. An hemo-
dynamic evaluation was performed in 44 patients, allowing
determination of pulmonary arterial pressures and cardiac
index. All procedures were approved by the appropriate
ethics committee, and subjects provided informed consent
to participate in the study.
Exercise tests. Exercise tests were all performed on a
bicycle, in an upright position. After an initial workload of
20 W, load was increased by 10 W every minute. Patients
were regularly encouraged to pedal until exhaustion at a
constant rate. All tests were stopped because of fatigue
and/or dyspnea. Heart rate was continuously recorded.
Brachial arterial pressure was measured with a mercury
manometer at each stage. Respiratory gases were analyzed
on a CPX-D Medical Graphics (Minneapolis, MN) system.
The equipment was calibrated with a standard gas mixture
before each test. Subjects breathed through a mouthpiece
with a nose clip. Oxygen consumption (VO2), carbon
dioxide production, minute ventilation and the respiratory
exchange ratio were measured on a breath by breath basis.
Peak oxygen consumption was defined as the highest
averaged oxygen consumption during the test and was
expressed in ml/min and ml/min/kg. Indexed peak oxygen
consumption (%) was calculated as peak oxygen consump-
tion divided by maximal predicted oxygen consumption
(23). The chronotropic reserve was defined as peak minus
rest heart rate/rest heart rate. The ventilatory threshold (24)
was determined by use of a combination of multiple
graphical methods (25). All patients exercised beyond the
anaerobic threshold, and the respiratory exchange ratio was
always greater than 1.0 at the end of exercise.
123Iodine metaiodobenzylguanidine scintigraphy.
Within 15 days of the exercise test, patients underwent
myocardial scintigraphy to determine MIBG uptake, used
as an index of neuronal norepinephrine reuptake. As
exercise-induced myocardial ischemia may decrease MIBG
uptake (26,27), a free period of at least 5 days was respected
between the exercise test and MIBG scintigraphy when the
exercise test was performed first. After a 30-min resting
period, patients were injected intravenously with 3 to 4 mCi
(111 to 148 MBq) of 123I MIBG (CIS BIO-International,
Gif sur Yvette, France). Twenty minutes (early acquisition)
and 4 h (late acquisition) after MIBG administration, a
10-min static acquisition was performed in the anterior view
of the chest on a Sopha Medical DST gamma-camera (Buc,
France). Cardiac MIBG uptake was measured as the heart
to mediastinum activity ratio (H/M) on a planar image by
two independent observers. Left ventricular activity was
recorded using a manually drawn region of interest and
mediastinum activity using a 7 3 7 pixel region of interest
placed over the upper mediastinum area (19). For each
patient, the H/M value was taken as the average of
measurements performed over his scintigraphic image by
each observer. The normal late H/M ratio obtained in our
laboratory from 20 normal subjects (mean age 48 6 18
years, range 23 to 78) is 192 6 42% (19).
The washout (WO) rate of MIBG within the myocar-
dium was measured as the percent of change in cardiac
activity from early to delayed images within the left ventric-
ular regions of interest as follows: (H early 2 H delayed) 3
100/H early, H values being corrected for 123I physical
decay.
Follow-up. Outcome was assessed either directly (when
the patient’s physician was a member of the medical staff),
or by contacting the patient’s practitioner. The date and
cause of death were documented in every case. Ten patients
died, and 23 patients underwent cardiac transplantation
during follow-up (10 6 8 months). Since there is no
consensus about the best way to consider heart transplan-
tation in survival analyses, we used two methods of analysis:
first using both death and transplantation as end points (33
Abbreviations and Acronyms
CHF 5 chronic heart failure
EF 5 ejection fraction
H/M 5 heart/mediastinum
MIBG 5 metaiodobenzylguanidine
NYHA 5 New York Heart Association
ROC 5 receiver operating characteristic
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events); second, censoring patients who underwent cardiac
transplantation at the time of intervention (considering
them alive at this time) (10 events).
Statistical analysis. Numeric values are expressed as
means 6 standard deviation. Differences between the means
of groups was made by analysis of variance or a Student t
test when appropriate. Linear regression analysis was by
least square. P values of 0.05 or less were considered to
denote statistically significant differences.
We used the Survival Analysis module of Stat View 4.02
(Abacus Concept, California) for MacIntosh software to
analyze survival. Kaplan–Meier cumulative mortality curves
were plotted to the end of follow-up to describe trends in
mortality over time in each of the risk categories (28). For
continuous variables, we used the medians as cutoff values.
Survival curves were compared by using the log-rank test.
Age, NYHA class, left ventricular ejection fraction,
end-diastolic diameter, early and late MIBG H/M, WO
and peak oxygen uptake were the variables entered in the
univariate analysis. The Cox proportional hazards regression
model was used to determine the significance of variables
predictive of outcome by univariate analysis (p , 0.05) as
independent predictors of survival in multivariate analysis
(backward selection) (29).
Finally, the sensitivity and specificity of values of MIBG
H/M and peak oxygen uptake for the prediction of death or
of death and cardiac transplantation were determined.
Receiver operating characteristic (ROC) curves were con-
structed by plotting sensitivity against (1 2 specificity). The
best compromise between sensitivity and specificity was
determined graphically.
RESULTS
Baseline values. Mean left ventricular ejection fraction was
25 6 10%. Mean echocardiographic left ventricular end-
diastolic and end-systolic diameters were 70 6 10 mm and
59 6 11 mm, respectively. Pulmonary wedge pressure was
16 6 8 mm Hg and cardiac index was 2.6 6 0.7 liters/
min/kg in the subgroup of patients in whom they were
measured.
Peak VO2 was on average 1493 6 490 ml/min, that is,
20.1 6 6.0 ml/min/kg (median value 21 ml/min/kg),
corresponding to 67 6 19% of the predicted value. A
ventilatory threshold could be clearly determined in 77
patients, and its mean value was 13.3 6 4.4 ml/min/kg.
Heart rate was 86 6 23 min21 at rest and 141 6 28 min21
at peak exercise, corresponding to 86 6 16% of the
predicted values. The chronotropic reserve was 137 6 11%.
Early MIBG H/M ratio was 139 6 21% (median 138%,
range 94% to 208%) and late MIBG H/M ratio was 131 6
20% (median 127%, range 88% to 191%). Washout was
34.8 6 6.0 (median 35.5, range 16.9 to 56.3).
Relation with hemodynamic and exercise variables. Late
MIBG H/M correlated with left ventricular ejection frac-
tion (r 5 0.49, p , 0.0001), cardiac index (r 5 0.40, p ,
0.01), mean pulmonary artery pressure (r 5 20.36, p ,
0.01), pulmonary artery resistances (r 5 20.30, p , 0.05)
and pulmonary wedge pressure (r 5 20.35, p , 0.05). The
correlation coefficients between late MIBG H/M and left
ventricular end-diastolic and end-systolic diameters and
fractional shortening were r 5 20.45, r 5 20.53 and r 5
20.43, respectively (all p , 0.001). Early MIBG H/M
correlated with late MIBG H/M (r 5 0.87, p , 0.0001)
and with the same hemodynamic parameters, albeit less
closely. Washout did not correlate with any hemodynamic
variable, except ejection fraction and mean pulmonary
arterial pressure.
There was a significant correlation between peak VO2 (in
ml/min/kg) and late MIBG H/M (r 5 0.41, p , 0.0001)
(Fig. 1). Expressing peak VO2 in ml/min or in percentage of
the predicted values did not change the coefficient of
correlation (r 5 0.41 and r 5 0.40, respectively, both p ,
0.0001). When the 12 patients with beta-blockers were
excluded, the coefficient of correlation was r 5 0.48. The
anaerobic threshold also correlated with MIBG uptake (r 5
0.35, p , 0.05). There was no correlation between MIBG
uptake and the chronotropic reserve (r 5 0.17, p 5 NS),
even when patients receiving beta-blockers were excluded.
Prognostic analysis. Patients who died or received trans-
plants had significantly lower peak VO2 and poorer NYHA
class than those who survived at the end of the study (Table
1). There was no or only marginal differences among the
two groups regarding age, ejection fraction, left ventricular
diameters and early and late H/M MIBG or WO.
Survival curves were drawn to identify the factors most
predictive of prognosis. Peak oxygen consumption was
highly predictive of event-free survival (cutoff median val-
ues: 21 ml/min/kg, chi-square 5 15, p 5 0.0001; and 69%
of the predicted values: chi-square 5 16, p , 0.0001) (Fig.
2). The median late MIBG H/M cutoff value of 127% also
discriminated between patients with good and poor out-
Figure 1. Correlation between late MIBG uptake (MIBG H/M,
in percentage) and peak VO2 (in ml/min/kg).
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come (chi-square 5 9, p 5 0.002) (Fig. 3). Early MIBG
had lower prognostic value, whereas WO did not have any.
By univariate analysis (Table 2), peak VO2 (p 5 0.0001)
and late MIBG H/M (p 5 0.04) were predictive of death or
heart transplantation. Neither early MIBG H/M nor WO
had prognostic value. Ejection fraction was not discrimi-
nant. By multivariate analysis (Table 3), only peak VO2
remained as an independent predictor of outcome.
When deaths only were considered, only peak VO2 (p ,
0.05) predicted death by univariate analysis. When patients
who underwent heart transplantation were excluded from
analysis, similar results were obtained (peak VO2: p 5 0.02;
late MIBG H/M: p 5 0.06).
Finally, ROC curves (Fig. 4) showed a greater area
under the curve for peak oxygen uptake than for early or
late MIBG H/M, confirming the better prognostic value
of the former for predicting death or death and trans-
plantation.
Figure 2. Event-free survival curves according to baseline peak
VO2, using a peak VO2 cutoff value of 21 ml/min/kg.
Figure 3. Event-free survival curves according to baseline late
MIBG uptake, with a MIBG H/M cutoff value of 127%.
Table 1. Description of Baseline Values in Patients Who Died, in Patients Who Underwent
Cardiac Transplantation and in Patients Who Survived
Death
(n 5 10)
Cardiac
Transplantation
(n 5 23)
Alive
(n 5 60) p
Age (mean 6 SD) 56 6 10 53 6 9 56 6 10 0.30
NYHA class 0.054
% I–II 20 13 55
% III–IV 80 87 45
Etiology 0.16
% ischemic 10 39 23
% nonischemic 90 61 77
Peak VO2 (ml/min)
(mean 6 SD)
1,310 6 539 1,267 6 509 1,610 6 440 0.007
Peak VO2 (ml/min/kg)
(mean 6 SD)
17.5 6 5.3 17.0 6 5.6 21.7 6 5.7 0.002
Peak VO2 (% predicted)
(mean 6 SD)
58 6 15 56 6 15 72 6 17 0.0001
EF (%) (mean 6 SD) 21 6 8 23 6 9 26 6 11 0.15
End-diastolic diameter (mm)
(mean 6 SD)
71 6 12 70 6 10 70 6 10 0.81
Late MIBG H/M (%)
(mean 6 SD)
123 6 14 128 6 21 134 6 20 0.18
Early MIBG H/M (%)
(mean 6 SD)
133 6 19 138 6 22 141 6 20 0.48
WO (mean 6 SD) 34.5 6 4.2 34.1 6 6.2 36.1 6 6.2 0.30
EF 5 ejection fraction; H/M 5 heart/mediastinum; MIBG 5 metaiodobenzylguanidine; NYHA 5 New York Heart
Association; WO 5 early to late MIBG H/M ratio.
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DISCUSSION
This study suggests that altered adrenergic nerve function
may determine in part exercise capacity and has a prognostic
value, which seems, however, to be lesser than that of peak
VO2.
Metaiodobenzylguanidine uptake in heart failure. Al-
tered adrenergic function is a hallmark of the syndrome of
heart failure. Abnormal baroreflex function (30), increased
spillover of noradrenaline (31) and sympathetic discharge
(32,33), down-regulation of the beta-adrenergic receptors
(4) and depletion of myocardial sympathetic stores (3) are
characteristic features of the disease and probably participate
in its pathophysiology. These alterations result in altered
contractile state and peripheral vasoconstriction. Cardiac
neuronal uptake is the predominant means for terminating
the action on beta-adrenoceptors of norepinephrine either
released by nerve terminals or removed from coronary
circulation (34) and is decreased in chronic heart failure
(8,9); this may lead to increased stimulation and down-
regulation of beta-adrenoceptors. Metaiodobenzylguanidine
myocardial scintigraphy has been shown to explore nor-
adrenaline reuptake within the cardiac synapse (6,7) and
thus has the potential to mirror the whole myocardial
adrenergic pathway disintegrity. Metaiodobenzylguanidine
uptake correlates with the norepinephrine content of the
heart (10) and with the increase in myocardial contractility
induced by intracoronary beta-adrenergic stimulation (35).
Metaiodobenzylguanidine uptake was clearly decreased in
our population, although some patients were found to have
Figure 4. Plot showing ROC curves for prediction of death or
cardiac transplantation for peak oxygen uptake (% of predicted
values) and late MIBG H/M. Peak oxygen uptake ROC curve,
situated clearly leftward relative to MIBG curve, suggests better
predictive value.
Table 2. Univariate Survival Analysis: Cox Model
Event: Deaths
(n 5 10)
Events: Deaths or
Transplantations
(n 5 33)
Risk
Ratio p
Risk
Ratio p
Age (years) 1.023 0.47 0.99 0.78
NYHA
I–II 1 1
III–IV 4.1 0.07 5.3 0.0006
Peak VO2 (%) 0.97 0.04 0.96 0.0001
Peak VO2 (ml/min) 0.99 0.03 0.99 0.0001
Peak VO2 (ml/min/kg) 0.89 0.03 0.88 0.0001
EF (%) 0.96 0.20 0.97 0.13
Late MIBG H/M (%) 0.03 0.09 0.11 0.04
Early MIBG H/M (%) 0.07 0.16 0.25 0.15
WO 1.008 0.90 1.05 0.14
End-diastolic diameter (mm) 1.001 0.68 1.001 0.68
Abbreviations as in Table 1.
Table 3. Multivariate Survival Analysis: Cox Model With a
Backward Selection
Events: Deaths
(n 5 10)
p
Events: Deaths
or
Transplantations
(n 5 33)
p
Age (years) 0.34 0.74
NYHA class 0.56 0.02
Peak VO2: % predicted 0.04 0.01
Late MIBG H/M (%) 0.27 0.87
Age (years) 0.30 0.81
NYHA class 0.57 0.02
Peak VO2: % predicted 0.047 0.01
Early MIBG H/M (%) 0.23 0.69
Abbreviations as in Table 1.
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MIBG uptake values only slightly lower than normal,
despite clear left ventricular dysfunction; in a recent exper-
imental study, it was found that MIBG uptake was not
decreased in the early stages of heart failure (36), a finding
also recently observed in men (37). Metaiodobenzylguani-
dine uptake decrease may thus be a late event in the history
of the disease, explaining its prognostic value in end-stage
heart failure (19). We found that MIBG uptake correlated
with most hemodynamic indexes of left ventricular dysfunc-
tion, albeit sometimes loosely.
Metaiodobenzylguanidine washout rate. Metaiodoben-
zylguanidine uptake within the myocardium decreases with
time, and there is evidence that the washout rate of MIBG
(WO) measured by calculating the early/late MIBG uptake
can be an index of norepinephrine spillover. Various studies
demonstrated that the nonneural myocardial uptake of
MIBG contributes mainly to the early image and disappears
rapidly, whereas the neural uptake contributes to the de-
layed images (14,38). These findings indicate that the
delayed image represents adrenergic nervous system func-
tion more faithfully than does the early image. Myocardial
retention of MIBG is significantly reduced, and conse-
quently MIBG washout increased in the patients with heart
failure (7,12,38,39). We found no additional value of
performing early MIBG imaging or calculating WO. In
contrast with other studies in mitral stenosis (17) or heart
failure (16), the WO did not appear to correlate with
hemodynamic parameters or peak VO2, nor did it have
prognostic value. Therefore, its medical interest is question-
able in patients with CHF.
Metaiodobenzylguanidine uptake and exercise capacity.
To our knowledge, no study has attempted to address the
relationship between the abnormalities of cardiac norepi-
nephrine reuptake and the circulatory response during
exercise in patients with CHF. We found a significant
correlation between MIBG uptake and peak VO2. This
suggests that the alteration in cardiac adrenergic function
may participate in the reduction in exercise tolerance.
Adrenergic responsiveness may influence both the contrac-
tile (40) and the chronotropic reserves (41). Eisenhofer et al.
(9) recently showed that norepinephrine reuptake efficiency
is decreased during exercise in heart failure, which may
contribute to increased sympathetic drive. Reduced chrono-
tropic reserve, an abnormality the prognostic value of which
has been recently emphasized (42), is frequently observed in
patients with chronic heart failure (41,43) and has been
related more to postsynaptic beta-adrenergic desensitization
than to altered norepinephrine kinetics. This may explain
the close correlation found in a previous study between the
extent of the chronotropic reserve and right ventricular
myocardial beta-adrenergic receptor density (44), whereas
we found no correlation between MIBG uptake and the
chronotropic reserve. Overall, abnormalities of the adrener-
gic nerve function explain at best 17% of the variance of
peak VO2; this underscores the importance of the other
determinants of peak VO2, mainly the peripheral ones.
Prognostic value of peak VO2 and MIBG uptake. The
increase in plasma norepinephrine has a negative impact on
prognosis in CHF patients (45). Increased cardiac sympa-
thetic nervous activity seems to have a greater prognostic
value than whole-body sympathetic activity, determined by
isotope dilution (46). Metaiodobenzylguanidine uptake,
which largely reflects altered cardiac noradrenergic pathway
dysfunction, has been found in a previous study to have
prognostic value in patients with end-stage CHF (19).
Subsequently, this parameter has demonstrated its powerful
value in the process of triage of patients referred for cardiac
transplantation (20). In that study (19), patients had severe
heart failure, and those who underwent cardiac transplan-
tation were excluded from analysis; in addition, exercise
capacity was not assessed. On the contrary, numerous
studies have demonstrated the great short-term prognostic
value of peak VO2 (21,45,47–49). Recently, we found that
peak VO2 also had prognostic value in the long term (22).
Therefore, we decided to prospectively compare the prog-
nostic value of both parameters. This study is the first
comparing the prognostic value of these two variables in
patients with various degrees of heart failure. We found that
both had greater prognostic value than ejection fraction, and
that peak VO2 seems to have a greater prognostic value than
MIBG uptake, whatever the way of analyzing outcome.
Moreover, in this population, MIBG imaging does not
seem to bring significant prognostic information beyond
that provided by peak VO2.
Limitations of the study. There are some potential limi-
tations to the present study. As patients remained medi-
cated during the investigation, one cannot exclude that the
effects of CHF therapy upon MIBG uptake may have
slightly modified the relationships: MIBG uptake was
reported to increase after spironolactone (50), angiotensin-
converting enzyme inhibitors (51) and perhaps digoxin and
amiodarone (52); beta-blocker therapy seems to have neu-
tral effect (53). We did not perform tomographic imaging
(54). However, in our experience as well as in others’ (12),
it is difficult and often impossible to obtain adequate
tomographic scans, at least 3 to 4 h after injection, especially
in the most severe patients; the reconstruction process is not
reproducible enough from one trained observer to another.
Myocardial perfusion was not simultaneously assessed by
201 thallium imaging (55). Decrease in perfusion by itself
may decrease planar MIBG uptake. However, previous
studies have shown that in either ischemic or idiopathic
dilated cardiomyopathy, resting myocardial blood flow val-
ues were close to normal. Finally, the number of deaths was
low, and this was the reason why we decided to consider
transplantation as an end point. It is unlikely that peak VO2
or MIBG values differently affected the decision to perform
cardiac transplantation, as at the time of the study, we felt
that both tests were roughly equally discriminant regarding
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the decision of transplantation. Censoring transplantation at
the time of surgery or only considering “urgent” transplan-
tation (not reported) did not change the results of the study.
It is, however, possible that the prognostic value of MIBG
imaging would be greater in patients with severe heart
failure. Recently, however, it was shown that even in
patients with the most advanced heart failure, peak VO2
indexed by predicted values yielded the greatest prognostic
value, as also noticed in other populations with a wide range
of heart failure (22,48,56,57).
Conclusions. Metaiodobenzylguanidine uptake, which re-
flects the reuptake of noradrenaline within the cardiac
synapse, only modestly correlates with peak VO2. Thus,
although alterations of the sympathetic pathway participate
in the alteration of the exercise response in patients with
CHF, they are not major determinants of peak VO2.
Metaiodobenzylguanidine uptake is a new powerful prog-
nostic variable with prognostic value greater than ejection
fraction. The MIBG uptake washout rate does not provide
any significant prognostic insight. However, in these pa-
tients with predominantly moderate heart failure, peak VO2
remains the better prognostic index.
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